Mynvax
11 known investors
Find your way into Mynvax
Mynvax develops engineered protein subunit vaccines using a protein stabilization platform, including influenza vaccine candidates based on stabilized hemagglutinin regions and thermo-tolerant vaccines against SARS-CoV-2 variants. Incubated at the Indian Institute of Science, the biotech startup collaborates with research labs, CDMOs, and vaccine manufacturers, with some programs funded by Indian government agencies.
Investors · 11
BIRAC✓ verifiedNew Delhi
SID Venture Partners✓ verifiedKyiv · $200K
1Crowd
LVX VenturesBangalore · $179K – $10M
Accelreported · 2 sourcesPalo Alto · $1.6M – $70M
Also in the syndicate · 6
1CwordInviga Healthcare FundleadKotak Investment AdvisorsKotak InvestmentsLegacy Assets LLPLets Venture
Funding
SEC filings, press & company announcements$6.8M disclosed across 2 rounds · 2021–2024
- $2.6Mextended Series A roundMay 2024 · 2 sources
Accel (lead), Inviga Healthcare Fund (lead), 1Cword, Kotak Investments, Legacy Assets LLP, Lets Venture
Source ↗ - $4.2MSeries AJul 2021 · 3 sources
Accel (lead), 1Crowd, Kotak Investment Advisors, Lets Venture
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Mynvax do?
- Mynvax develops engineered protein subunit vaccines using a protein stabilization platform, including influenza vaccine candidates based on stabilized hemagglutinin regions and thermo-tolerant vaccines against SARS-CoV-2 variants. Incubated at the Indian Institute of Science, the biotech startup collaborates with research labs, CDMOs, and vaccine manufacturers, with some programs funded by Indian government agencies.
- Who are Mynvax's investors?
- Mynvax's investors include BIRAC, SID Venture Partners, 1Crowd, LVX Ventures, Accel.
- How much funding has Mynvax raised?
- Mynvax has disclosed $6.8M raised across 2 rounds.